JP2013501224A - 葉酸を標的とした診断及び処置 - Google Patents

葉酸を標的とした診断及び処置 Download PDF

Info

Publication number
JP2013501224A
JP2013501224A JP2012523104A JP2012523104A JP2013501224A JP 2013501224 A JP2013501224 A JP 2013501224A JP 2012523104 A JP2012523104 A JP 2012523104A JP 2012523104 A JP2012523104 A JP 2012523104A JP 2013501224 A JP2013501224 A JP 2013501224A
Authority
JP
Japan
Prior art keywords
tumor
patient
treatment
folate receptor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501224A5 (enExample
Inventor
リーモン，クリストファー，ポール
メスマン，リチャード
モルゲンシュテルン，ダーヴィト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of JP2013501224A publication Critical patent/JP2013501224A/ja
Publication of JP2013501224A5 publication Critical patent/JP2013501224A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • G01N33/5752—
    • G01N33/57545—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012523104A 2009-07-31 2010-07-30 葉酸を標的とした診断及び処置 Pending JP2013501224A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23059509P 2009-07-31 2009-07-31
US61/230,595 2009-07-31
US34644410P 2010-05-19 2010-05-19
US61/346,444 2010-05-19
US35102210P 2010-06-03 2010-06-03
US61/351,022 2010-06-03
PCT/US2010/043992 WO2011014821A1 (en) 2009-07-31 2010-07-30 Folate-targeted diagnostics and treatment

Publications (2)

Publication Number Publication Date
JP2013501224A true JP2013501224A (ja) 2013-01-10
JP2013501224A5 JP2013501224A5 (enExample) 2013-09-12

Family

ID=43529728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523104A Pending JP2013501224A (ja) 2009-07-31 2010-07-30 葉酸を標的とした診断及び処置

Country Status (13)

Country Link
US (2) US20120128587A1 (enExample)
EP (1) EP2460013A4 (enExample)
JP (1) JP2013501224A (enExample)
KR (1) KR20120050462A (enExample)
CN (2) CN104857534A (enExample)
AU (1) AU2010278734A1 (enExample)
BR (1) BR112012002064A2 (enExample)
CA (1) CA2769754A1 (enExample)
IL (1) IL217744A0 (enExample)
IN (1) IN2012DN01708A (enExample)
NZ (1) NZ598145A (enExample)
RU (1) RU2012105641A (enExample)
WO (1) WO2011014821A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012065079A1 (en) 2010-11-12 2012-05-18 Endocyte, Inc. Methods of treating cancer
CN103607891A (zh) * 2011-04-12 2014-02-26 恩多塞特公司 固体药用组合物
JP6892218B2 (ja) 2012-11-15 2021-06-23 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
JP6595463B2 (ja) 2013-10-16 2019-10-23 ユニベルシテ リブレ デ ブリュッセル 気道に影響する増殖性疾患の処置に有用な製剤
EP3415489A1 (en) 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
ES2860173T3 (es) 2013-11-19 2021-10-04 Purdue Research Foundation Método de selección de pacientes para inflamación
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20170368208A1 (en) * 2015-01-11 2017-12-28 Endocyte, Inc. Cancer imaging agent
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2018182776A1 (en) * 2016-03-29 2018-10-04 Endocyte, Inc. Folate conjugate for use in targeting tumor associated macrophages
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
WO2017205661A1 (en) * 2016-05-25 2017-11-30 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2008051525A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Methods of treating ovarian cancer
JP2008537778A (ja) * 2005-03-30 2008-09-25 パーデュー・リサーチ・ファウンデーション 細胞の葉酸ビタミン受容体の定量化による癌予後診断法
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2512867C (en) * 2003-01-27 2014-08-26 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
JP5243041B2 (ja) * 2004-12-21 2013-07-24 ネクター セラピューティックス 安定化ポリマーチオール試薬
US20070276231A1 (en) * 2004-12-23 2007-11-29 Low Philip S Positron Emission Tomography Imaging Method
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008537778A (ja) * 2005-03-30 2008-09-25 パーデュー・リサーチ・ファウンデーション 細胞の葉酸ビタミン受容体の定量化による癌予後診断法
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2008051525A2 (en) * 2006-10-25 2008-05-02 Schering Corporation Methods of treating ovarian cancer
WO2009002993A1 (en) * 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6014035002; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｏｎｃｏｌｏｇｙ Ｖｏｌ．２５，Ｎｏ．１８Ｓ（Ｊｕｎｅ　２０　Ｓｕｐｐｌ．）, 2007, ２５７７ *
JPN6014035005; Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．６７，Ｎｏ．９, 2007, ｐ．４４３４-４４４２ *
JPN6014035008; Ｉｎｔ．Ｊ．Ｃａｎｃｅｒ Ｖｏｌ．１２１, 2007, ｐ．１５８５-１５９２ *
JPN6014035010; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｎｕｃｌｅａｒ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．４９，Ｎｏ．６, 2008, ｐ．８９９-９０６ *
JPN6014035012; Ｐｒｏｃ．　Ａｍ．　Ａｓｓｏｃ．Ｃａｎｃｅｒ　Ｒｅｓ．　Ａｎｎｕａｌ　Ｍｅｅｔｉｎｇ Ｖｏｌ．５０, 200904, ｐ．４３９，Ａｂｓｔｒａｃｔ＃１８２５ *
JPN6014035014; ドキソルビシン塩酸塩リポソーム注射剤添付文書，ｈｔｔｐ：／／ｃｓｗｓ．ｔｏｋｙｏ-ｍｅｄ．ａｃ．ｊｐ／ｃｓｗｓ／ｄｒｕｇｉｎｆｏ／Ｄｏｘｉｌ％２０ＰＩ％２０ *

Also Published As

Publication number Publication date
EP2460013A1 (en) 2012-06-06
US20140140925A1 (en) 2014-05-22
BR112012002064A2 (pt) 2017-05-09
AU2010278734A1 (en) 2012-02-23
WO2011014821A1 (en) 2011-02-03
KR20120050462A (ko) 2012-05-18
NZ598145A (en) 2014-10-31
IN2012DN01708A (enExample) 2015-06-05
CN102549434A (zh) 2012-07-04
US20120128587A1 (en) 2012-05-24
IL217744A0 (en) 2012-03-29
EP2460013A4 (en) 2013-04-03
CN104857534A (zh) 2015-08-26
RU2012105641A (ru) 2013-09-10
CA2769754A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
JP2013501224A (ja) 葉酸を標的とした診断及び処置
JP2019520328A (ja) Ｐｅｔイメージング用免疫修飾因子
JP2013542264A (ja) 癌を処置する方法
JP2017503763A (ja) Ｇｃｃ発現細胞を撮像するための化合物及び組成物
EP2795317B1 (en) Composition for use in a method for cancer selection
JP7692839B2 (ja) コンジュゲート及びそのイメージング剤としての使用
CN119095629A (zh) 用于癌症患者的诊断方法
US20240131206A1 (en) Peptide receptor radionuclide therapy
HK1172952A (en) Folate-targeted diagnostics and treatment
JP2023536268A (ja) 特にｃｃｋｂ受容体陽性の癌もしくは腫瘍の処置および／または診断に使用するための、ラパログと放射標識ガストリンアナログとを含む組成物
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
CA3234495A1 (en) Combination therapy of radionuclide complex
WO2025251001A1 (en) N-(2-(-2-cyano-4-fluoropyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide tracer and uses in pet imaging
KR20250109190A (ko) 암의 식별 및/또는 치료
WO2023164769A1 (en) Radiopharmaceutical and methods
WO2025235951A1 (en) Radiopharmaceutical compositions for actinium in targeted radionuclide therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150826

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170106